Overall survival was not significantly different between treatment groups at this final prespecified analysis.
Related Posts
- [Articles] Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
The addition of enzalutamide to standard of care showed sustained improvement in overall survival for…
- [Articles] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Tislelizumab plus chemotherapy as a first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma…
- [Articles] Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
Belzutifan plus cabozantinib has promising antitumour activity in patients with pretreated clear cell renal cell…